NPI: 1477549756 · LITTLE ROCK, AR 72205 · General Acute Care Hospital · NPI assigned 09/22/2005
Authorized official GEORGE, AMANDA controls 20+ related entities in our dataset. Read more
| Authorized Official | GEORGE, AMANDA (ASSOC VC FOR CLINICAL FINANCE) |
| NPI Enumeration Date | 09/22/2005 |
Other providers sharing the same authorized official: GEORGE, AMANDA
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 498,994 | $9.32M |
| 2019 | 545,700 | $12.41M |
| 2020 | 479,335 | $12.06M |
| 2021 | 496,031 | $13.21M |
| 2022 | 558,025 | $16.03M |
| 2023 | 558,768 | $14.27M |
| 2024 | 446,600 | $9.89M |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 1,900 | 1,384 | $8.85M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 49,398 | 34,568 | $4.20M |
| J2350 | Injection, ocrelizumab, 1 mg | 474 | 299 | $4.03M |
| T1015 | Clinic visit/encounter, all-inclusive | 237,100 | 178,927 | $2.49M |
| 59025 | Fetal non-stress test | 18,437 | 11,279 | $2.48M |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | 5,567 | 5,118 | $1.83M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 12,949 | 11,512 | $1.47M |
| 80048 | Basic metabolic panel (calcium, ionized) | 120,071 | 80,590 | $1.38M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 33,371 | 30,587 | $1.33M |
| J9312 | Injection, rituximab, 10 mg | 691 | 274 | $1.31M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 32,553 | 29,869 | $1.29M |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 7,593 | 6,586 | $1.19M |
| J2505 | Injection, pegfilgrastim, 6 mg | 1,205 | 637 | $1.14M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1,679 | 1,494 | $1.06M |
| 78816 | 1,578 | 1,361 | $1.05M | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 34,382 | 32,303 | $1.01M |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | 7,361 | 6,697 | $918K |
| 80053 | Comprehensive metabolic panel | 61,252 | 48,145 | $901K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 7,755 | 4,970 | $832K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 14,665 | 11,594 | $830K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 11,299 | 9,548 | $809K |
| 70450 | Computed tomography, head or brain; without contrast material | 9,244 | 8,078 | $783K |
| 94761 | 51,422 | 29,731 | $779K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 5,908 | 5,388 | $767K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 20,297 | 18,436 | $764K |
| 86901 | 33,198 | 28,297 | $740K | |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | 1,045 | 327 | $737K |
| 85027 | 117,695 | 91,951 | $724K | |
| 74183 | 1,526 | 1,395 | $708K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 113,651 | 79,011 | $705K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 63,418 | 49,985 | $686K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 20,431 | 6,783 | $626K |
| 36415 | Collection of venous blood by venipuncture | 45,597 | 31,122 | $614K |
| 84443 | Thyroid stimulating hormone (TSH) | 35,598 | 31,673 | $598K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 6,760 | 5,214 | $570K |
| J1459 | Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg | 896 | 373 | $564K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 2,945 | 2,669 | $550K |
| J0585 | Injection, onabotulinumtoxina, 1 unit | 3,982 | 2,158 | $543K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | 2,392 | 2,167 | $529K |
| 72125 | Computed tomography, cervical spine; without contrast material | 4,793 | 4,248 | $521K |
| 86780 | 31,169 | 28,850 | $505K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 52,428 | 40,150 | $505K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | 2,237 | 2,020 | $474K |
| 62370 | 2,427 | 2,022 | $470K | |
| 87150 | 9,917 | 9,416 | $468K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 11,031 | 9,747 | $455K |
| 72141 | 2,096 | 1,891 | $453K | |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | 10,371 | 9,260 | $445K |
| 82247 | 51,886 | 37,640 | $434K | |
| 70496 | 2,959 | 2,597 | $431K | |
| 83615 | 55,911 | 39,989 | $399K | |
| 70498 | 2,720 | 2,383 | $399K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 19,084 | 17,146 | $385K |
| 80051 | 28,847 | 21,022 | $368K | |
| 84450 | 58,292 | 42,874 | $365K | |
| 72156 | 1,038 | 949 | $361K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5,685 | 4,511 | $358K |
| 64642 | 1,650 | 1,334 | $350K | |
| 87340 | 30,057 | 28,058 | $347K | |
| 83735 | 70,933 | 40,763 | $336K | |
| 82565 | 46,188 | 35,537 | $332K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 6,634 | 4,732 | $327K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 9,597 | 7,632 | $324K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | 3,281 | 3,077 | $315K |
| 84075 | 50,862 | 36,906 | $314K | |
| 36430 | 2,715 | 1,816 | $313K | |
| 84460 | 51,118 | 37,444 | $313K | |
| 86803 | 21,976 | 20,092 | $312K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | 37,030 | 32,482 | $307K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 4,082 | 2,778 | $307K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | 1,268 | 1,109 | $299K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 2,112 | 1,894 | $296K |
| 82310 | 32,511 | 23,704 | $281K | |
| 64615 | 1,363 | 1,179 | $275K | |
| 71046 | Radiologic examination, chest; 2 views | 20,989 | 18,200 | $271K |
| 70491 | 2,327 | 2,120 | $261K | |
| 99499 | 15,193 | 12,522 | $255K | |
| 84484 | 32,568 | 19,545 | $254K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 29,702 | 27,217 | $253K |
| 87536 | 3,878 | 3,534 | $251K | |
| J1725 | Injection, hydroxyprogesterone caproate, 1 mg | 373 | 118 | $251K |
| 80061 | Lipid panel | 24,893 | 22,453 | $242K |
| 87486 | 7,538 | 6,536 | $242K | |
| 87581 | 7,533 | 6,535 | $242K | |
| 82977 | 37,048 | 28,093 | $236K | |
| 83880 | 9,703 | 8,134 | $235K | |
| 80050 | General health panel | 5,663 | 5,112 | $231K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 6,368 | 3,954 | $223K |
| 72157 | 673 | 624 | $221K | |
| 86762 | 12,109 | 11,356 | $215K | |
| 67028 | Intravitreal injection of a pharmacologic agent | 944 | 855 | $210K |
| 49083 | 1,335 | 644 | $207K | |
| J7307 | Etonogestrel (contraceptive) implant system, including implant and supplies | 359 | 310 | $206K |
| 96361 | Intravenous infusion, hydration; each additional hour | 3,286 | 2,334 | $199K |
| 72146 | 940 | 835 | $198K | |
| 84100 | 65,393 | 37,474 | $197K | |
| 81025 | 27,564 | 23,755 | $194K | |
| 96367 | 1,582 | 1,088 | $192K | |
| 20552 | 1,187 | 1,043 | $190K | |
| 74174 | 1,024 | 935 | $189K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 4,203 | 4,030 | $182K |
| 36591 | 5,367 | 3,286 | $179K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 192 | 98 | $175K |
| 73221 | 901 | 808 | $171K | |
| 71250 | 2,273 | 2,080 | $170K | |
| 72158 | 486 | 442 | $166K | |
| 70486 | 1,619 | 1,478 | $163K | |
| 80074 | 3,396 | 3,024 | $155K | |
| 83021 | 7,488 | 6,336 | $154K | |
| 82728 | 13,663 | 11,962 | $153K | |
| 81002 | 39,768 | 25,592 | $150K | |
| 38222 | 1,494 | 1,295 | $148K | |
| 88185 | 3,320 | 2,572 | $146K | |
| 84520 | 35,238 | 26,228 | $146K | |
| 82962 | 39,541 | 20,293 | $145K | |
| 86900 | 33,187 | 28,300 | $145K | |
| 82607 | 12,841 | 11,584 | $144K | |
| 86850 | 32,880 | 28,175 | $143K | |
| 96415 | 2,867 | 1,984 | $141K | |
| 81001 | 41,775 | 33,689 | $141K | |
| C1769 | Guide wire | 1,259 | 1,159 | $139K |
| 88184 | 7,042 | 5,538 | $138K | |
| 97161 | 2,990 | 2,628 | $136K | |
| 72197 | 273 | 243 | $133K | |
| J9310 | Injection, rituximab, 100 mg | 82 | 26 | $133K |
| 76830 | Ultrasound, transvaginal | 2,948 | 2,688 | $132K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 3,493 | 3,274 | $132K |
| 64405 | 904 | 822 | $131K | |
| J9035 | Injection, bevacizumab, 10 mg | 76 | 37 | $130K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2,404 | 2,130 | $129K |
| 64616 | 623 | 517 | $128K | |
| 93308 | 3,478 | 3,097 | $125K | |
| 71045 | Radiologic examination, chest; single view | 17,011 | 14,295 | $125K |
| 87497 | 6,721 | 3,893 | $122K | |
| 87077 | 12,021 | 10,756 | $122K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | 8,873 | 4,242 | $122K |
| 88142 | 7,709 | 7,258 | $120K | |
| J0475 | Injection, baclofen, 10 mg | 1,197 | 961 | $117K |
| 31575 | 940 | 866 | $115K | |
| J0185 | Injection, aprepitant, 1 mg | 1,161 | 548 | $114K |
| 83970 | 5,890 | 4,980 | $114K | |
| 82784 | 9,164 | 6,374 | $107K | |
| 93975 | 2,652 | 2,405 | $104K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2,293 | 1,611 | $101K |
| 84466 | 11,097 | 9,807 | $99K | |
| 90715 | 4,990 | 4,629 | $99K | |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | 1,798 | 1,704 | $99K |
| 95700 | 841 | 748 | $99K | |
| 95713 | 653 | 575 | $96K | |
| J9299 | Injection, nivolumab, 1 mg | 41 | 24 | $96K |
| 88307 | 1,758 | 1,505 | $95K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1,310 | 1,054 | $93K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | 2,091 | 2,032 | $93K |
| J7050 | Infusion, normal saline solution, 250 cc | 5,254 | 2,716 | $93K |
| 77066 | Tomosynthesis, mammo | 1,558 | 1,444 | $93K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 677 | 622 | $92K |
| 85610 | 23,678 | 18,599 | $91K | |
| 84439 | 10,508 | 9,423 | $90K | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | 152 | 125 | $88K |
| 83690 | 15,031 | 12,751 | $88K | |
| 82570 | 23,170 | 17,632 | $86K | |
| 88341 | 1,371 | 1,207 | $85K | |
| 86140 | 16,856 | 11,060 | $81K | |
| 87522 | Neg quan hep c or qual rna | 2,952 | 2,672 | $81K |
| 82950 | 13,293 | 12,655 | $80K | |
| 76820 | 1,535 | 843 | $80K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 4,963 | 4,153 | $79K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 3,174 | 1,358 | $78K |
| 90686 | 6,941 | 6,490 | $77K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 2,214 | 1,801 | $75K |
| Q3014 | Telehealth originating site facility fee | 19,439 | 16,693 | $75K |
| 87040 | 6,346 | 3,730 | $73K | |
| 86920 | 1,988 | 1,657 | $73K | |
| 94010 | 4,191 | 3,838 | $73K | |
| J9145 | Injection, daratumumab, 10 mg | 65 | 25 | $72K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | 432 | 374 | $69K |
| 86704 | 7,322 | 6,629 | $68K | |
| 76821 | 1,308 | 744 | $68K | |
| 0001A | 3,272 | 3,149 | $67K | |
| 86706 | 8,285 | 7,526 | $67K | |
| 76642 | 2,924 | 2,368 | $66K | |
| 84702 | 6,700 | 4,625 | $66K | |
| 73630 | 3,553 | 3,142 | $65K | |
| 96377 | 540 | 379 | $65K | |
| 76536 | 2,377 | 2,159 | $64K | |
| 99285 | Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8,106 | 6,943 | $64K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 2,844 | 2,593 | $64K |
| J9045 | Injection, carboplatin, 50 mg | 951 | 614 | $63K |
| 82040 | 7,169 | 5,683 | $63K | |
| 94729 | 3,249 | 2,965 | $62K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 5,364 | 4,620 | $61K |
| 0002A | 2,931 | 2,848 | $60K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 4,097 | 3,065 | $60K |
| 97001 | 1,437 | 1,361 | $59K | |
| 97162 | 1,080 | 971 | $59K | |
| 88342 | 3,018 | 2,656 | $59K | |
| 86334 | 4,890 | 3,571 | $58K | |
| 94726 | 3,158 | 2,894 | $58K | |
| 82232 | 2,787 | 2,183 | $58K | |
| 51798 | 641 | 575 | $57K | |
| 92134 | 7,778 | 6,881 | $56K | |
| 99283 | Emergency department visit for the evaluation and management, moderate severity | 5,389 | 4,602 | $56K |
| 82746 | 5,287 | 4,751 | $56K | |
| 80197 | 14,386 | 6,679 | $56K | |
| 83605 | 5,563 | 3,740 | $56K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | 4,321 | 3,836 | $56K |
| 84156 | 19,165 | 13,396 | $55K | |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 43 | 24 | $54K |
| 83521 | 2,750 | 1,705 | $54K | |
| 84165 | 7,119 | 4,696 | $54K | |
| 77065 | Tomosynthesis, mammo | 1,263 | 1,124 | $54K |
| 87070 | 4,711 | 4,052 | $53K | |
| 73130 | 3,142 | 2,808 | $53K | |
| 83540 | 11,209 | 9,887 | $52K | |
| 87186 | 8,358 | 7,443 | $51K | |
| 81003 | 26,442 | 21,642 | $51K | |
| 73562 | 2,175 | 1,934 | $51K | |
| 82248 | 12,910 | 9,726 | $50K | |
| 93351 | 421 | 400 | $50K | |
| J3489 | Injection, zoledronic acid, 1 mg | 338 | 285 | $49K |
| 72195 | 263 | 231 | $47K | |
| 73590 | 2,581 | 2,229 | $47K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 10,111 | 4,759 | $45K |
| 73610 | 3,066 | 2,562 | $44K | |
| J9041 | Injection, bortezomib, 0.1 mg | 347 | 102 | $44K |
| 80047 | 1,680 | 1,133 | $44K | |
| 87205 | 9,775 | 8,475 | $43K | |
| 90677 | 402 | 320 | $43K | |
| 86709 | 4,858 | 4,415 | $43K | |
| 76801 | 1,272 | 1,140 | $43K | |
| 73030 | 2,814 | 2,433 | $42K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | 1,573 | 1,454 | $42K |
| 97165 | 879 | 766 | $42K | |
| 87507 | 161 | 126 | $42K | |
| 72131 | 467 | 434 | $41K | |
| J2323 | Injection, natalizumab, 1 mg | 15 | 14 | $41K |
| 99284 | Emergency department visit for the evaluation and management, high severity | 5,242 | 4,584 | $40K |
| 82947 | 7,446 | 6,329 | $40K | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 1,572 | 729 | $40K |
| 87641 | 1,858 | 1,687 | $40K | |
| 73502 | 2,276 | 1,968 | $39K | |
| 80076 | 4,175 | 3,780 | $39K | |
| 87631 | 632 | 590 | $38K | |
| J0485 | Injection, belatacept, 1 mg | 924 | 426 | $38K |
| 84145 | 2,309 | 1,829 | $37K | |
| 86235 | 1,139 | 1,026 | $37K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 11,423 | 8,015 | $36K |
| 82951 | 2,172 | 2,071 | $36K | |
| 82435 | 6,171 | 5,151 | $36K | |
| 82077 | 2,945 | 2,508 | $36K | |
| 72100 | 2,001 | 1,817 | $36K | |
| 73560 | 2,083 | 1,788 | $35K | |
| 84403 | 1,611 | 1,374 | $34K | |
| 80164 | 2,476 | 2,001 | $34K | |
| 84153 | 2,301 | 2,032 | $33K | |
| 64483 | 192 | 177 | $33K | |
| 84132 | 6,043 | 4,988 | $33K | |
| 64644 | 156 | 133 | $33K | |
| 76604 | 2,221 | 1,974 | $32K | |
| 82105 | 2,479 | 2,208 | $32K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1,622 | 1,374 | $32K |
| 87177 | 3,100 | 2,861 | $32K | |
| 82805 | 1,321 | 1,062 | $32K | |
| 31579 | 203 | 182 | $32K | |
| 82533 | 1,897 | 1,473 | $31K | |
| 85007 | 11,405 | 8,168 | $31K | |
| 86038 | 3,264 | 2,952 | $30K | |
| 85730 | 5,890 | 4,852 | $30K | |
| 43235 | 214 | 193 | $30K | |
| 86923 | 2,712 | 2,042 | $30K | |
| 85379 | 3,363 | 2,835 | $30K | |
| 73552 | 1,991 | 1,804 | $29K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 252 | 220 | $29K |
| 84295 | 6,337 | 5,251 | $29K | |
| 36592 | 1,005 | 667 | $28K | |
| 86160 | 3,476 | 1,640 | $28K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | 18,564 | 13,877 | $28K |
| 84550 | 8,198 | 5,494 | $28K | |
| 82043 | 5,946 | 5,443 | $27K | |
| 87305 | 3,629 | 1,865 | $26K | |
| 82670 | 962 | 836 | $26K | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 823 | 738 | $26K |
| 10060 | 157 | 151 | $26K | |
| 92557 | 1,688 | 1,541 | $25K | |
| 84481 | 1,781 | 1,606 | $25K | |
| 82378 | 1,551 | 1,377 | $25K | |
| 95811 | 238 | 221 | $25K | |
| 84146 | 1,277 | 1,079 | $25K | |
| 31231 | 152 | 140 | $25K | |
| 85055 | 2,223 | 1,744 | $24K | |
| 80069 | 1,826 | 1,340 | $24K | |
| 86592 | 5,807 | 5,326 | $24K | |
| 77001 | 305 | 262 | $24K | |
| 96417 | 1,049 | 692 | $24K | |
| 82550 | 4,370 | 3,629 | $23K | |
| 92133 | 3,298 | 3,021 | $23K | |
| J7030 | Infusion, normal saline solution , 1000 cc | 2,334 | 1,577 | $23K |
| 83001 | 1,228 | 1,116 | $23K | |
| 87081 | 2,698 | 2,408 | $22K | |
| 83520 | 1,932 | 1,377 | $22K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 5,931 | 4,129 | $21K |
| 77085 | 1,349 | 1,273 | $21K | |
| J2785 | Injection, regadenoson, 0.1 mg | 431 | 377 | $20K |
| 71020 | 1,711 | 1,554 | $20K | |
| 72170 | 1,441 | 1,263 | $20K | |
| 64400 | 139 | 123 | $19K | |
| 52000 | 170 | 156 | $19K | |
| 86225 | 2,020 | 1,789 | $19K | |
| 97003 | 493 | 465 | $19K | |
| 64493 | 100 | 86 | $19K | |
| 93971 | 502 | 456 | $19K | |
| 36593 | 117 | 91 | $19K | |
| 86922 | 453 | 357 | $18K | |
| 96376 | 3,149 | 1,778 | $17K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | 99 | 95 | $17K |
| 74230 | 802 | 714 | $17K | |
| 86480 | 282 | 260 | $16K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | 1,054 | 493 | $16K |
| 85652 | 7,428 | 6,663 | $16K | |
| 95951 | 252 | 221 | $16K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | 215 | 116 | $16K |
| 99152 | 2,138 | 1,825 | $16K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | 308 | 290 | $15K |
| 82375 | 1,316 | 1,062 | $15K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 10,598 | 8,390 | $15K |
| J1953 | Injection, levetiracetam, 10 mg | 654 | 458 | $15K |
| 91320 | 309 | 291 | $14K | |
| 94760 | 906 | 805 | $14K | |
| 11100 | 114 | 106 | $14K | |
| 87449 | 2,395 | 1,492 | $14K | |
| 85384 | 1,729 | 1,229 | $14K | |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | 162 | 143 | $14K |
| 88720 | 2,465 | 2,017 | $14K | |
| V2632 | Posterior chamber intraocular lens | 118 | 102 | $14K |
| 82330 | 1,662 | 1,245 | $14K | |
| 72190 | 687 | 618 | $14K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | 1,837 | 1,783 | $13K |
| 71271 | 353 | 333 | $13K | |
| G0202 | Screening mammography, bilateral (2-view study of each breast), including computer-aided detection (cad) when performed | 339 | 337 | $13K |
| 88313 | 2,232 | 1,819 | $13K | |
| 86870 | 1,163 | 963 | $13K | |
| 82575 | 874 | 809 | $13K | |
| 82140 | 1,905 | 1,589 | $13K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 13,432 | 10,451 | $13K |
| 92611 | 819 | 730 | $13K | |
| 93270 | 612 | 588 | $13K | |
| 76937 | 1,454 | 1,255 | $13K | |
| 76819 | Fetal biophysical profile; without non-stress testing | 863 | 543 | $12K |
| 87210 | 2,538 | 2,076 | $12K | |
| 86481 | 1,155 | 1,055 | $12K | |
| 93296 | 1,083 | 995 | $12K | |
| 85046 | 3,253 | 2,541 | $12K | |
| J9263 | Injection, oxaliplatin, 0.5 mg | 45 | 24 | $12K |
| 74178 | 132 | 117 | $12K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 502 | 461 | $12K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 573 | 522 | $12K |
| 90670 | 314 | 283 | $12K | |
| 73110 | 622 | 540 | $11K | |
| 87799 | 4,765 | 2,904 | $11K | |
| 72040 | 620 | 564 | $11K | |
| 80143 | 885 | 768 | $11K | |
| 77062 | 226 | 202 | $11K | |
| 82952 | 2,157 | 2,056 | $11K | |
| 51701 | 140 | 136 | $11K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 678 | 554 | $11K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 1,178 | 790 | $11K |
| J1453 | Injection, fosaprepitant, 1 mg | 406 | 249 | $11K |
| 36561 | 51 | 51 | $11K | |
| 85097 | 234 | 215 | $11K | |
| 58100 | 69 | 55 | $10K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | 672 | 624 | $10K |
| 90870 | 509 | 152 | $10K | |
| 80179 | 786 | 697 | $10K | |
| G0008 | Administration of influenza virus vaccine | 2,344 | 2,227 | $10K |
| 73090 | 691 | 596 | $9K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1,174 | 1,091 | $9K |
| 77061 | 247 | 211 | $9K | |
| 99401 | 985 | 938 | $9K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | 3,621 | 2,259 | $9K |
| 87493 | 355 | 314 | $9K | |
| 92083 | 1,289 | 1,189 | $9K | |
| 71270 | 49 | 43 | $9K | |
| 76770 | 361 | 334 | $9K | |
| 86696 | 518 | 461 | $9K | |
| 99153 | Mod sedat endo service >5yrs | 1,600 | 1,397 | $9K |
| 84134 | 1,091 | 886 | $9K | |
| 80185 | 689 | 553 | $8K | |
| 87015 | 1,168 | 972 | $8K | |
| 74018 | 681 | 568 | $8K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | 112 | 101 | $8K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 3,066 | 2,005 | $8K |
| 88311 | 1,235 | 1,073 | $7K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 697 | 632 | $7K |
| J3480 | Injection, potassium chloride, per 2 meq | 3,438 | 2,360 | $7K |
| 69210 | 86 | 77 | $7K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 289 | 258 | $7K |
| 91200 | 760 | 707 | $7K | |
| 83883 | 504 | 314 | $7K | |
| 86304 | 361 | 300 | $7K | |
| 82610 | 1,124 | 947 | $7K | |
| 92567 | 958 | 884 | $7K | |
| J7298 | Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg | 14 | 12 | $7K |
| 77084 | 44 | 40 | $7K | |
| 88304 | 286 | 257 | $7K | |
| G0475 | Hiv antigen/antibody, combination assay, screening | 3,281 | 2,879 | $6K |
| 0004A | 748 | 650 | $6K | |
| 77003 | 125 | 104 | $6K | |
| 87102 | 586 | 475 | $6K | |
| 83050 | 1,295 | 1,049 | $6K | |
| 73060 | 444 | 386 | $6K | |
| 87075 | 651 | 513 | $6K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 9,580 | 6,594 | $6K |
| 95886 | 198 | 189 | $6K | |
| 96401 | 249 | 107 | $6K | |
| 80178 | 932 | 768 | $6K | |
| 90746 | 199 | 184 | $6K | |
| 83002 | 307 | 276 | $6K | |
| 82150 | 1,088 | 935 | $6K | |
| 88172 | 107 | 94 | $5K | |
| 64643 | 171 | 150 | $5K | |
| 76514 | 489 | 439 | $5K | |
| J0897 | Injection, denosumab, 1 mg | 13 | 12 | $5K |
| 86695 | 518 | 461 | $5K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 47 | 42 | $5K |
| 86593 | 1,086 | 962 | $5K | |
| 87147 | 657 | 590 | $5K | |
| 87517 | 259 | 225 | $5K | |
| 73080 | 333 | 297 | $5K | |
| 86146 | 168 | 126 | $5K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 7,604 | 6,494 | $5K |
| G0378 | Hospital observation service, per hour | 7,042 | 5,293 | $5K |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | 20 | 18 | $5K |
| 88264 | 41 | 38 | $5K | |
| 76512 | 162 | 139 | $5K | |
| 0071A | 118 | 106 | $5K | |
| 82374 | 1,107 | 976 | $5K | |
| 86147 | 152 | 138 | $5K | |
| 87206 | 1,030 | 810 | $5K | |
| J9267 | Injection, paclitaxel, 1 mg | 302 | 172 | $5K |
| J3370 | Injection, vancomycin hcl, 500 mg | 2,484 | 1,406 | $4K |
| 96368 | 81 | 51 | $4K | |
| 92136 | 298 | 262 | $4K | |
| 87184 | 591 | 543 | $4K | |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 823 | 441 | $4K |
| 85014 | 2,007 | 1,487 | $4K | |
| 73700 | 43 | 38 | $4K | |
| 87116 | 518 | 445 | $4K | |
| 86800 | 307 | 281 | $4K | |
| 85018 | 2,148 | 1,599 | $4K | |
| 84480 | 274 | 254 | $4K | |
| G0204 | Diagnostic mammography, including computer-aided detection (cad) when performed; bilateral | 108 | 105 | $4K |
| 0124A | 267 | 260 | $4K | |
| 0054A | 238 | 206 | $4K | |
| 86431 | 789 | 723 | $4K | |
| 84154 | 357 | 321 | $4K | |
| 95874 | 488 | 425 | $4K | |
| 0003A | 236 | 207 | $4K | |
| 80195 | 293 | 189 | $4K | |
| 90732 | 565 | 530 | $3K | |
| 72128 | 28 | 26 | $3K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 30 | 25 | $3K |
| C1726 | Catheter, balloon dilatation, non-vascular | 83 | 72 | $3K |
| 72202 | 334 | 318 | $3K | |
| J9190 | Injection, fluorouracil, 500 mg | 610 | 270 | $3K |
| 0072A | 75 | 67 | $3K | |
| 84681 | 196 | 184 | $3K | |
| J0690 | Injection, cefazolin sodium, 500 mg | 5,390 | 3,997 | $3K |
| 51702 | 58 | 54 | $3K | |
| 64635 | 17 | 13 | $3K | |
| 82803 | 177 | 160 | $3K | |
| 97166 | 63 | 56 | $3K | |
| J1644 | Injection, heparin sodium, per 1000 units | 3,616 | 2,014 | $3K |
| 90636 | 39 | 39 | $3K | |
| 84703 | 452 | 375 | $3K | |
| 90480 | 160 | 159 | $3K | |
| 76775 | 219 | 201 | $3K | |
| 72070 | 173 | 156 | $3K | |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 56 | 36 | $3K |
| 89051 | 532 | 464 | $3K | |
| 93356 | 170 | 150 | $3K | |
| 93017 | 134 | 126 | $3K | |
| 57454 | 12 | 12 | $3K | |
| 71010 | 346 | 327 | $3K | |
| 82103 | 292 | 266 | $3K | |
| 82010 | 349 | 295 | $3K | |
| J1447 | Injection, tbo-filgrastim, 1 microgram | 22 | 14 | $3K |
| 88173 | 225 | 205 | $3K | |
| J1750 | Injection, iron dextran, 50 mg | 19 | 13 | $2K |
| J1815 | Injection, insulin, per 5 units | 2,160 | 1,144 | $2K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 2,577 | 2,049 | $2K |
| 11102 | 29 | 28 | $2K | |
| 86376 | 210 | 199 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | 41 | 31 | $2K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 138 | 64 | $2K |
| 84432 | 141 | 133 | $2K | |
| 62323 | 16 | 14 | $2K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 17 | 15 | $2K |
| 86200 | 187 | 178 | $2K | |
| 19083 | 13 | 12 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 11,194 | 9,663 | $2K |
| 77080 | 57 | 50 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | 2,065 | 1,584 | $2K |
| J0780 | Injection, prochlorperazine, up to 10 mg | 3,353 | 2,455 | $2K |
| 86335 | 167 | 149 | $2K | |
| 84300 | 614 | 548 | $2K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 19 | 18 | $2K |
| 86301 | 157 | 147 | $2K | |
| 85396 | 525 | 403 | $2K | |
| 86832 | 84 | 67 | $2K | |
| 94060 | 43 | 41 | $2K | |
| 92015 | Determination of refractive state | 3,838 | 3,543 | $2K |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 21 | 14 | $2K |
| 90656 | 149 | 143 | $2K | |
| 86833 | 84 | 67 | $1K | |
| J1170 | Injection, hydromorphone, up to 4 mg | 4,689 | 2,786 | $1K |
| 96411 | 36 | 26 | $1K | |
| 83930 | 239 | 214 | $1K | |
| 95911 | 54 | 46 | $1K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 10,913 | 6,672 | $1K |
| 80156 | 112 | 100 | $1K | |
| 76882 | 119 | 111 | $1K | |
| 87902 | 28 | 26 | $1K | |
| 93454 | 19 | 15 | $1K | |
| 74022 | 60 | 53 | $1K | |
| 86902 | 172 | 134 | $1K | |
| 88312 | 122 | 107 | $1K | |
| 93458 | 16 | 12 | $1K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 3,172 | 2,543 | $1K |
| 93321 | 43 | 37 | $1K | |
| P9040 | Red blood cells, leukocytes reduced, irradiated, each unit | 74 | 50 | $1K |
| J1790 | Injection, droperidol, up to 5 mg | 1,537 | 1,314 | $1K |
| J1940 | Injection, furosemide, up to 20 mg | 2,100 | 1,261 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 114 | 105 | $1K |
| 72082 | 42 | 37 | $1K | |
| 86352 | 401 | 242 | $1K | |
| 88237 | 15 | 15 | $1K | |
| 10005 | 15 | 12 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 6,142 | 4,818 | $968.53 |
| 85049 | 375 | 151 | $948.80 | |
| 88108 | 71 | 60 | $930.88 | |
| 43762 | 14 | 14 | $919.68 | |
| 0225U | 1,154 | 1,019 | $882.72 | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 121 | 101 | $878.97 |
| 95813 | 15 | 12 | $813.93 | |
| 82390 | 136 | 127 | $807.72 | |
| 0064A | 90 | 85 | $803.90 | |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | 210 | 199 | $766.90 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,883 | 2,594 | $758.70 |
| 83090 | 63 | 53 | $735.57 | |
| 83516 | 258 | 206 | $722.61 | |
| 0012A | 160 | 153 | $702.28 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | 928 | 682 | $702.04 |
| 83010 | 62 | 43 | $696.56 | |
| 93297 | 148 | 136 | $681.42 | |
| 80177 | 158 | 137 | $654.01 | |
| J2997 | Injection, alteplase recombinant, 1 mg | 33 | 24 | $644.19 |
| 0011A | 167 | 155 | $641.31 | |
| 11900 | 16 | 15 | $640.01 | |
| 92250 | 92 | 86 | $623.63 | |
| 84166 | 64 | 54 | $622.18 | |
| 84155 | 107 | 87 | $584.78 | |
| 80158 | 61 | 37 | $581.20 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 198 | 145 | $564.43 |
| 85613 | 111 | 103 | $552.06 | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 483 | 455 | $525.38 |
| 82274 | 26 | 26 | $511.06 | |
| J8540 | Dexamethasone, oral, 0.25 mg | 2,307 | 1,213 | $501.00 |
| 95910 | 13 | 13 | $483.94 | |
| 87324 | 107 | 90 | $482.40 | |
| 72083 | 15 | 13 | $433.76 | |
| 92020 | 119 | 109 | $426.59 | |
| 90662 | 821 | 773 | $415.25 | |
| 73551 | 45 | 39 | $409.82 | |
| A4648 | Tissue marker, implantable, any type, each | 14 | 12 | $403.22 |
| G0257 | Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility | 111 | 74 | $395.20 |
| 0031A | 20 | 18 | $369.20 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 997 | 856 | $365.08 |
| 95970 | 77 | 69 | $344.11 | |
| 83525 | 36 | 30 | $331.92 | |
| 86364 | 28 | 27 | $325.20 | |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | 388 | 357 | $324.11 |
| 76857 | 15 | 12 | $321.00 | |
| 86705 | 51 | 39 | $309.88 | |
| 86039 | 44 | 42 | $302.86 | |
| 74000 | 18 | 14 | $300.00 | |
| J0461 | Injection, atropine sulfate, 0.01 mg | 552 | 441 | $255.52 |
| 72110 | 12 | 12 | $243.94 | |
| 85306 | 15 | 14 | $240.79 | |
| 73600 | 13 | 12 | $240.00 | |
| 89060 | 26 | 24 | $211.16 | |
| 93225 | 16 | 14 | $202.30 | |
| 82272 | 69 | 59 | $200.80 | |
| 85303 | 14 | 13 | $197.50 | |
| 73620 | 14 | 13 | $181.41 | |
| S0164 | Injection, pantoprazole sodium, 40 mg | 355 | 207 | $173.27 |
| 84157 | 41 | 39 | $170.00 | |
| 85300 | 12 | 12 | $169.30 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 508 | 469 | $169.26 |
| 82945 | 42 | 38 | $169.13 | |
| 93280 | 12 | 12 | $168.38 | |
| 88302 | 15 | 12 | $164.88 | |
| J2791 | Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu | 50 | 50 | $157.34 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 1,522 | 1,262 | $149.29 |
| 87640 | 77 | 64 | $148.46 | |
| G0123 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision | 110 | 88 | $142.60 |
| 80202 | 20 | 13 | $135.38 | |
| 93242 | 15 | 13 | $126.64 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 10,140 | 7,593 | $117.86 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 295 | 242 | $106.39 |
| 86708 | 133 | 120 | $91.93 | |
| 92610 | 32 | 27 | $81.15 | |
| J2704 | Injection, propofol, 10 mg | 485 | 317 | $78.68 |
| J1630 | Injection, haloperidol, up to 5 mg | 322 | 249 | $78.66 |
| S0028 | Injection, famotidine, 20 mg | 2,751 | 1,932 | $78.41 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 1,147 | 1,032 | $77.43 |
| 96379 | 41 | 25 | $75.00 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 378 | 345 | $64.85 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 955 | 734 | $63.74 |
| 84133 | 13 | 12 | $42.98 | |
| J7999 | Compounded drug, not otherwise classified | 2,012 | 1,702 | $42.07 |
| 94618 | 12 | 12 | $40.08 | |
| 94642 | 49 | 39 | $36.88 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 71 | 52 | $32.69 |
| G0328 | Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous | 12 | 12 | $31.61 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 334 | 231 | $30.31 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 96 | 67 | $30.23 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 146 | 119 | $27.87 |
| J0456 | Injection, azithromycin, 500 mg | 29 | 24 | $24.32 |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | 13 | 13 | $21.14 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 250 | 227 | $19.76 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | 63 | 38 | $17.44 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 200 | 157 | $13.37 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 1,800 | 1,222 | $3.63 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 55 | 49 | $3.60 |
| J1171 | Injection, hydromorphone, 0.1 mg | 39 | 23 | $1.28 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 1,105 | 586 | $1.17 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 192 | 142 | $0.83 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 326 | 273 | $0.74 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 300 | 251 | $0.64 |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 107 | 96 | $0.23 |
| G8985 | Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 31 | 29 | $0.12 |
| G8984 | Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals | 30 | 29 | $0.11 |
| C9113 | Injection, pantoprazole sodium, per vial | 449 | 175 | $0.04 |
| G8988 | Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 24 | 24 | $0.03 |
| G8987 | Self care functional limitation, current status, at therapy episode outset and at reporting intervals | 24 | 24 | $0.03 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 66 | 56 | $0.02 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 66 | 56 | $0.02 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 1,047 | 957 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 206 | 162 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 175 | 139 | $0.00 |
| 81241 | 15 | 13 | $0.00 | |
| J0688 | Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg | 73 | 60 | $0.00 |
| 84425 | 13 | 12 | $0.00 | |
| 97116 | 22 | 13 | $0.00 | |
| J3473 | Injection, hyaluronidase, recombinant, 1 usp unit | 13 | 12 | $0.00 |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | 14 | 13 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 257 | 209 | $0.00 |
| G0009 | Administration of pneumococcal vaccine | 143 | 142 | $0.00 |
| J3490 | Unclassified drugs | 18 | 14 | $0.00 |
| J8501 | Aprepitant, oral, 5 mg | 46 | 31 | $0.00 |
| 81240 | 13 | 12 | $0.00 | |
| 94660 | 20 | 12 | $0.00 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 15 | 12 | $0.00 |
| 86769 | 17 | 16 | $0.00 |